Currently there is no known predictive marker for the treatment outcome of ER+/HER2+ breast cancers [19], thus the ability of SERPINA1 to predict the survival of this intrinsic subtype of breast cancer patients is valuable. Here, ESR1 is linked to breast carcinoma.